tiprankstipranks
SciBase Holding AB (SE:SCIB)
:SCIB

SciBase Holding AB (SCIB) AI Stock Analysis

Compare
0 Followers

Top Page

SE:SCIB

SciBase Holding AB

(SCIB)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 5.2)
Rating:51Neutral
Price Target:
kr0.35
▲(6.67% Upside)
Action:ReiteratedDate:03/15/26
The score is held down primarily by weak financial performance—large operating losses, heavy cash burn, and a sharply reduced equity base—despite strong revenue growth. Technicals are a supportive offset with price above major moving averages and positive MACD, while valuation remains constrained by negative earnings and no dividend yield data.
Positive Factors
Recurring consumables model
The business earns recurring revenue from consumables and service tied to each procedure, creating predictable pull-through as the installed base grows. That model supports long-term revenue visibility, customer stickiness, and scalable unit economics as procedure volumes increase.
Negative Factors
Severe cash burn
Sustained and widening negative operating and free cash flow indicate the business is not self-funding and relies on external capital. Continued cash burn increases funding risk, potential dilution from equity raises, and limits ability to invest selectively without securing financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables model
The business earns recurring revenue from consumables and service tied to each procedure, creating predictable pull-through as the installed base grows. That model supports long-term revenue visibility, customer stickiness, and scalable unit economics as procedure volumes increase.
Read all positive factors

SciBase Holding AB (SCIB) vs. iShares MSCI Sweden ETF (EWD)

SciBase Holding AB Business Overview & Revenue Model

Company Description
SciBase Holding AB (SCIB) is a Swedish medical technology company that specializes in developing innovative diagnostic solutions for skin cancer detection and monitoring. The company operates primarily in the healthcare sector, focusing on non-inv...
How the Company Makes Money
SciBase generates revenue primarily from sales of its Nevisense system and recurring sales of related consumables and service items. Key revenue streams typically include: (1) system revenue from selling or placing Nevisense instruments with clini...

SciBase Holding AB Financial Statement Overview

Summary
Strong multi-year revenue growth and solid gross profit, but overall financial quality is pressured by very large and widening operating losses, sharply weaker equity in 2025, and accelerating negative operating/free cash flow.
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue40.46M29.70M23.25M17.89M11.73M
Gross Profit27.10M21.08M16.04M11.23M6.58M
EBITDA-81.49M-57.59M-51.83M-39.33M-38.58M
Net Income-87.06M-61.13M-55.59M-39.90M-41.69M
Balance Sheet
Total Assets52.17M61.73M64.33M49.85M85.46M
Cash, Cash Equivalents and Short-Term Investments22.60M11.24M34.12M18.83M65.61M
Total Debt0.004.18M6.80M8.12M2.86M
Total Liabilities45.51M25.08M21.28M24.62M14.66M
Stockholders Equity6.66M36.65M43.06M25.24M70.80M
Cash Flow
Free Cash Flow-84.81M-57.81M-52.37M-44.85M-40.12M
Operating Cash Flow-84.58M-57.38M-51.98M-44.47M-39.50M
Investing Cash Flow-228.00K-428.00K-383.00K-381.00K-526.00K
Financing Cash Flow96.29M34.91M67.68M-2.48M64.22M

SciBase Holding AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.33
Price Trends
50DMA
0.27
Positive
100DMA
0.26
Positive
200DMA
0.28
Positive
Market Momentum
MACD
0.02
Negative
RSI
76.86
Negative
STOCH
94.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Positive. The current price of 0.33 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.27, and above the 200-day MA of 0.28, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 76.86 is Negative, neither overbought nor oversold. The STOCH value of 94.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SCIB.

SciBase Holding AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
kr117.62M20.88
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
kr295.73M-1.43-253.54%36.15%26.67%
44
Neutral
kr143.37M-4.28-61.62%14.18%72.73%
44
Neutral
kr46.85M-2.89-60.56%163.12%30.50%
42
Neutral
kr88.64M-1.00-45.59%37.79%
41
Neutral
kr56.28M-7.37
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SCIB
SciBase Holding AB
0.36
-0.01
-3.25%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
4.60
1.80
64.29%
SE:LXB
Luxbright AB
0.36
-0.52
-58.86%
SE:ARCOMA
Arcoma AB
8.22
-1.76
-17.64%
SE:NEOLA
Neola Medical AB
0.72
-1.98
-73.26%
SE:ICO
Iconovo AB
1.19
-1.36
-53.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 15, 2026